针对IgA脏病的生物信息分析,临床影响和与铁死相关特征基因的实验验证
Tingting Liu1, Tingting Pan2, Mingxin Chang3
1Department of Nephrology, The First Hospital of Jilin University, Changchun, China.
Frontiers in medicine
|August 25, 2025
概括
双特异性酸酶1 (DUSP1) 被确定为免疫球蛋白A脏病 (IgAN) 中关键的铁化相关基因. 较低的DUSP1水平与疾病进展和免疫细胞透相关,为Igan提供了诊断和治疗潜力.
科学领域:
- 肝脏病学
- 细胞生物学
- 免疫学
背景情况:
- 免疫球蛋白A脏病 (IgAN) 是全球球体疾病的主要原因,具有复杂的致病机制.
- 铁,一种铁介导的细胞死亡途径,与各种疾病有关,但其在IgAN中的作用需要进一步阐明.
- 对于开发有效的诊断和治疗策略来说,了解IgAN中的ferroptosis激活至关重要.
研究的目的:
- 为了确定IgAN诊断的铁与相关的特征基因 (FFG).
- 在IgAN中研究FFG与脏免疫细胞透之间的关系.
- 探索FFG在IGAN病变中的潜在机制.
主要方法:
- 使用来自Igan患者和对照者的组织微阵列数据集.
- 使用机器学习算法 (LASSO,SVM-RFE,随机森林) 来选与铁死相关的FFG基因.
- 使用CIBERSORT和GSEA对Igan小鼠模型进行了验证,并分析了免疫细胞透.
主要成果:
- 通过三种机器学习算法,双特异性酶1 (DUSP1) 被确定为一个关键的FFG.
- 在IgAN组织中,DUSP1表达显著下调,与铁死标志物 (GPX4,SLC7A11/ xCT) 有正相关,与ACSL4有负相关.
- DUSP1参与MAPK,ERBB和JAK-STAT信号通路,并且与透的炎症前免疫细胞 (Tfh,NK,M1巨细胞) 有负相关性.
结论:
- 在IgAN诊断中,DUSP1是潜在的铁死相关生物标志物.
- DUSP1在IgAN病变中的作用包括调节铁和免疫细胞透.
- 这些发现对IgAN诊断和未来的治疗策略有重大影响.
更多相关视频
14:18Author Spotlight: Investigating the Potential of Chinese Herbal Medicinal Active Dioscin in Treating IgA Nephropathy
Published on: October 13, 2023
1.9K
04:01Author Spotlight: Tracing the Ferroptotic Signatures and Cell Death Dynamics in Medulloblastoma for Advanced Therapeutics
Published on: March 15, 2024
1.2K
相关概念视频
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
84
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
84
01:29Pharmacogenomics: Identification of New Drug Targets
129
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
129